Epigenetic signatures and risk determinants in bladder cancer: Implications for diagnostic and therapeutic interventions.

Within the broader urological landscape, bladder cancer (BC) continues to be a resilient malignancy, characterised by a burgeoning prevalence and an intricate etiological framework involving both genetic and environmental determinants. The development and spread of BC are also greatly influenced by sophisticated hijacking of epigenetic machinery, such as DNA methylation, histone tailoring, and miRNA-mediated interference, in addition to traditionalprimary sequence alterations. These aberrations orchestrate neoplastic transformation by triggering epigenetic silencing of tumour suppressors, constitutive hyperactivation of oncogenic drivers, and disruption of pivotal intracellular signalling cascades. Some proven etiological factors that contribute to the development of BC include smoking, occupational carcinogen exposure, recurrent urinary tract infections, environmental exposure to hazardous chemicals and genetic predisposition. Furthermore, bladder cancer patients face a heightened risk of metachronous malignancies in the lung, prostate and kidney driven by convergent etiologic landscapes and shared genomic vulnerabilities. This review provides a high-resolution map of the epigenetic landscape in bladder carcinoma, delineating the interplay between aberrant modifications and novel epigenetic therapeutics. By decoding the fundamental regulatory circuits of the epigenome, we aim to catalyse the discovery of high-fidelity biomarkers and precision targets, ultimately redefining the therapeutic paradigm to enhance patient survival.